CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 2018 Jan 19;: Authors: Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ, Australia National Health and Medical Research Council Development Grant, Cancer Institute NSW Translationl Program Grant Abstract Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease. We demonstrate that membrane CD83 is a diagnostic and therapeutic target, highly expressed in Hodgkin lymphoma cell lines and Hodgkin and Reed-Sternberg cells in 29/35 (82.9%) Hodgkin lymphoma patient lymph node biopsies. CD83 from Hodgkin lymphoma tumor cells was able to trogocytose to surrounding T cells and interestingly, the trogocytosing CD83+T cells expressed significantly more PD-1 compared to CD83- T cells. Hodgkin lymphoma tumor cells secreted soluble CD83 that inhibited T cell proliferation and anti-CD83 antibody partially reversed the inhibitory effect. High levels of soluble CD83 were detected in Hodgkin lymphoma patient sera and these returned to normal in patients who had good clinical responses to chemot...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research